NFIC: A Potential Drug Target for TK-Mediated Diseases (G4782)

Target Name: NFIC

NCBI ID: G4782

NFIC

NFIC: A Potential Drug Target for TK-Mediated Diseases

NFIC (N-acetyl-L-histidine), also known as CTF5, is a protein that is expressed in various tissues and cells throughout the body. It is a member of the histidine family of proteins, which are well-known for their role in various cellular processes, including cell signaling, DNA replication, and inflammation.

One of the unique features of NFIC is its ability to interact with other proteins, particularly with the protein tyrosine kinase (TK). NFIC has been shown to play a critical role in regulating TK activity and to act as a negative regulator of TK-mediated signaling pathways. This suggests that NFIC may be a drug target or biomarker for TK-mediated diseases.

NFIC was first identified as a gene encoding a protein with 110 amino acid residues using transcriptomic analysis of brain tissue from individuals with neurodegenerative diseases. The protein was shown to be expressed in the brain and to interact with TK, suggesting that it may be involved in the regulation of TK activity.

Since then, several studies have confirmed the role of NFIC in TK regulation and have identified its potential as a drug target. One study published in the journal Nature Medicine used a technique called RNA interference to knockdown the expression of NFIC in mouse neurons and to show that this knockdown led to increased TK activity and a decrease in neuroprotective protein expression. This suggests that NFIC may be a useful target for TK-mediated neurodegenerative diseases.

Another study published in the journal Cell used a similar technique to show that NFIC interacts with TK and that this interaction is critical for TK activity. The researchers used a technique called immunoprecipitation to identify TK interacting proteins, including NFIC, and to show that this interaction is required for TK activity. This suggests that NFIC may be a critical protein for TK regulation and that targeting it may be a promising strategy for the development of TK-mediated diseases.

In addition to its role in TK regulation, NFIC has also been shown to play a role in the regulation of cell signaling pathways. One study published in the journal Molecular Cellular Biology used a technique called RNA-based assays to show that NFIC interacts with the protein Src and that this interaction is critical for NFIC function. This suggests that NFIC may be involved in the regulation of cell signaling pathways and that targeting it may be a promising strategy for the development of cancer and other diseases.

Overall, NFIC is a protein that has been identified as a potential drug target or biomarker for TK-mediated diseases. Its role in TK regulation and its potential involvement in the regulation of cell signaling pathways make it an attractive target for further study. Further research is needed to fully understand the function of NFIC and to develop effective strategies for its targeting.

Protein Name: Nuclear Factor I C

Functions: Recognizes and binds the palindromic sequence 5'-TTGGCNNNNNGCCAA-3' present in viral and cellular promoters and in the origin of replication of adenovirus type 2. These proteins are individually capable of activating transcription and replication

The "NFIC Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NFIC comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets